A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

• ClinicalTrials.gov Identifier: NCT04400695
• Recruitment Status: Recruiting
• First Posted: May 22, 2020
• Last Update Posted: November 26, 2021
• Sponsor: RemeGen Co., Ltd.
• Information provided by (Responsible Party): RemeGen Co., Ltd.

Study Description

Brief Summary:

This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ，previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.

Condition or disease	Intervention/treatment	Phase
Breast Cancer	Drug: RC48-ADC; Drug: Paclitaxel Injection; Drug: Docetaxel Injection; Drug: Vinorelbine Tartrate Injection; Drug: Capecitabine Tablets	Phase 3

Detailed Description:

This study is a multi-center, randomized, open, parallel control to evaluate the effectiveness and safety of Phase III clinical trials of the efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody-Monomethyl auristatin E (MMAE) conjugate for the treatment of locally advanced or metastatic breast cancer the study.The low expression of HER2 is defined as: the immunohistochemistry (IHC) confirmed by the central laboratory detects the expression of HER2 protein as IHC 2+ and the fluorescence in situ hybridization (FISH) detection has no amplification.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 366 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
• Actual Study Start Date: September 29, 2020
• Estimated Primary Completion Date: December 31, 2022
• Estimated Study Completion Date: December 30, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: RC48-ADC; RC48-ADC common name：Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection Dosage form：Lyophilized powder injection specification：60 mg / piece Medication plan：Every 2 weeks Expiration date：18 months HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.	Drug: RC48-ADC; RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks; Other Name: RC48
Active Comparator: Physician's Choice; Physician's Choice: HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis. Physician's choice from the following options: Paclitaxel Injection Docetaxel Injection Vinorelbine Tartrate Injection Capecitabine Tablets	Drug: Paclitaxel Injection; Administered according to label, as one option for Physician's Choice (determined before randomization); Other Name: Taxol; Drug: Docetaxel Injection; Administered according to label, as one option for Physician's Choice (determined before randomization); Other Name: Taxotere; Drug: Vinorelbine Tartrate Injection; Administered according to label, as one option for Physician's Choice (determined before randomization); Other Name: Navelbine; Drug: Capecitabine Tablets; Administered according to label, as one option for Physician's Choice (determined before randomization); Other Name: Xeloda

Outcome Measures

Primary Outcome Measures :

1. Progression-free survival (PFS), evaluated by an independent efficacy evaluation committee [ Time Frame: within approximately 3 years ]
   Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.

Secondary Outcome Measures :

1. Progression-free survival (PFS), evaluated by the investigator [ Time Frame: within approximately 3 years ]
   Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.
2. Objective remission rate (ORR) [ Time Frame: within approximately 3 years ]
   The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed).
3. Duration of relief (DOR) [ Time Frame: within approximately 3 years ]
   DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death
4. Disease control rate (DCR) [ Time Frame: within approximately 3 years ]
   Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study.
5. Tumor progression time (TTP) [ Time Frame: within approximately 3 years ]
   Time to disease progression (TTP) refers to the time from the random date to the first disease progression (calculated by the event that occurred first). Disease progression will be evaluated by the investigator according to the RECIST 1.1 standard (investigator and Independent Review Committee(IRC) evaluation).
6. Overall survival (OS) [ Time Frame: within approximately 3 years ]
   Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Voluntarily agree to participate in the study and sign the informed consent;
• Subjects aged 18-70 years (including 18 years and 70 years) and not reaching the 71st birthday were all considered to be ≤70 years old;
• Expected survival ≥12 weeks;
• Eastern Cooperative Oncology Group(ECOG) physical condition 0 or 1;
• For female subjects of child-bearing age women agreed to study during treatment and experimental subjects within 6 months after the end of the treatment period using an approved by the medical contraception (e.g. intrauterine device, the pill or condoms), before the study drug delivery within 7 days of pregnancy blood test must be negative (sterilization surgery or age 60 or more subjects can choose no pregnancy blood test), and must be an lactation. For male subjects: should be sterilized surgically, or agree to use a medically approved contraceptive method during the study period and for 6 months after the end of the treatment period. Control subjects after the end of the treatment period according to the choice of control drugs to determine the length of contraception.
• Able to understand the study requirements and be willing and able to follow the study and follow-up procedures.
• Bone marrow function:

hemoglobin ≥9g/dL; absolute neutrophil count ≥1.5×109/L; white blood cell count ≥3.0×109/L platelet ≥100 ×109/L;

• Liver function (according to the normal value of the clinical trial center) :

serum total bilirubin ≤1.5 times the upper limit of normal value (ULN); alanine aminotransferase (ALT), aspartate aminotransferase(AST) and Alkaline phosphatase（ALP） were ≤2.5 × ULN in the absence of liver metastasis, and ALT, AST and Alkaline phosphatase(ALP) were ≤5 × ULN in the presence of liver metastasis

• Renal function (according to the normal value of the clinical trial center) :

serum creatinine ≤1.5×ULN, or calculated by Cockcroft-Gault formula, the creatinine clearance rate (CrCl) ≥60 mL/min;

• Cardiac function:

American New York college of cardiology (NYHA) grade < 3; left ventricular ejection fraction ≥50%;

• Breast cancer subjects diagnosed by histology and / or cytology are currently at a locally advanced or metastatic stage and cannot be radically removed;
• The low expression of HER2 confirmed by the IHC and FISH results of the central laboratory (defined as: IHC 2+ and no amplification of FISH); the subject can provide a specimen of the primary or metastatic tumor site (paraffin wax) for HER2 detection Block, paraffin-embedded section or fresh tissue section can be used);
• Previous use of anthracycline drugs;
• Received 1 or 2 systemic chemotherapy treatments after relapse / metastasis. Subjects who relapsed during adjuvant chemotherapy or within 12 months after the end of adjuvant chemotherapy were considered to have failed first-line chemotherapy after relapse / metastasis.
• Hormone receptors are negative or positive. Hormone receptor-positive subjects need to progress after receiving endocrine therapy after relapse / metastasis or relapse after less than 2 years. Patients who are not suitable for endocrine therapy can be included in this study after undergoing chemotherapy treatment (first-line or second-line);
• The imaging evidence confirmed by the investigator that the tumor disease progressed during or after the most recent treatment is required;
• There has been no diagnosis of HER2 positive (HER2 IHC 3+ or FISH amplification)
• Have not used drugs targeting HER2 (including antibodies, small molecule Tyrosine kinase inhibitor（TKIs） and antibody drug conjugates).
• According to the RECIST 1.1 standard, there is at least one measurable lesion.

Exclusion Criteria:

• Received chemotherapy within 4 weeks before the start of study administration (treatment with nitrosourea and mitomycin C within 6 weeks, oral fluorouracil within 2 weeks), radiotherapy (palliative for bone metastases Local radiotherapy is within 2 weeks before study administration), immunotherapy; received endocrine therapy for breast cancer within 2 weeks before study administration;
• The research drug was used within 4 weeks before the start of study administration;
• Have undergone major surgery within 4 weeks before the start of study administration;
• Have received a live vaccine within 4 weeks before the start of study administration or plan to receive any vaccine during the study period;
• Serious cardiovascular and cerebrovascular events occurred within 12 months, including but not limited to unstable angina, myocardial infarction, cerebral hemorrhage, and cerebral infarction (except for asymptomatic and untreated lacunar infarction)；
• Those who are suffering from heart disease are not suitable for enrollment, including but not limited to arrhythmia and heart failure requiring medical treatment or accompanied by symptoms;
• There are other lung diseases requiring treatment or serious, including but not limited to active pulmonary tuberculosis, interstitial lung disease, etc ;
• Suffering from active infection requiring systemic treatment;
• Have active autoimmune diseases (such as the use of corticosteroids or immunosuppressive drugs, etc.) that require systemic treatment within the past 2 years, allowing related alternative treatments (such as thyroxine, insulin, or the physiology of adrenal or pituitary insufficiency Corticosteroid replacement therapy);
• The toxicity of the previous anti-tumor therapy has not been restored to the 0 to 1 level defined by CTCAE version 5.0, of which the neurotoxicity has not been restored to 0; except for hair loss, pigmentation or other researches that do not increase the risk of medication Happening;
• Have a clear past or current history of neurological or mental disorders, including epilepsy or dementia;
• According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the clinical study；
• Positive HIV test results; patients with active hepatitis B or C (HBsAg positive and hepatitis B virus（HBV） DNA titers above the upper limit of normal; Hepatitis C Virus Antibody(HCVAb) positive hepatitis C virus （HCV） RNA titers above the upper limit of normal)；
• There is a third interstitial fluid that cannot be controlled by drainage or other methods (including a large amount of pleural effusion or ascites);
• Known hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or similar drugs;
• Subjects who are not suitable for using any of the alternative control drugs;
• The presence of brain metastases and / or cancerous meningitis;
• Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured);
• Subjects who are estimated to be inadequate for patients to participate in this clinical study or other factors that the investigator believes are inappropriate to participate in this study;

Contacts and Locations

Contacts

Contact: Binghe Xu, M.D.; 010-87788826; bhxu@hotmail.com

Locations

China, Beijing

Oncology Hospital, Chinese Academy of Medical Sciences; Recruiting

Beijing, Beijing, China, 100021

Contact: Binghe Xu 010-87788826 bhxu@hotmail.com

Sponsors and Collaborators

RemeGen Co., Ltd.

Investigators

• Principal Investigator: Binghe Xu; Oncology Hospital, Chinese Academy of Medical Sciences
• Principal Investigator: Tao Sun; Liaoning Tumor Hospital & Institute
• Principal Investigator: Wei Li; Jilin University First Hospital
• Principal Investigator: Yuee Teng; First Affiliated Hospital of China Medical University
• Principal Investigator: Shu Wang; Peking University People's Hospital
• Principal Investigator: Xiaojia Wang; Zhejiang Cancer Hospital
• Principal Investigator: Min Yan; Henan Cancer Hospital
• Principal Investigator: Jifeng Feng; Jiangsu Cancer Institute & Hospital
• Principal Investigator: Ying Cheng; Jilin Provincial Tumor Hospital
• Principal Investigator: Ying Wang; Sun Yat-sen Memorial Hospital,Sun Yat-sen University
• Principal Investigator: Ying Wang; Sun Yat-sen University Cancer Prevention and Control Center
• Principal Investigator: Ning Liao; Guangdong Provincial People's Hospital
• Principal Investigator: Haibo Wang; Qingdao University Hospital
• Principal Investigator: Quchang Ouyang; Hunan Cancer Hospital
• Principal Investigator: Yueyin Pan; Anhui Provincial Hospital
• Principal Investigator: Yingying Du; The First Affiliated Hospital of Anhui Medical University
• Principal Investigator: Changlu Hu; Anhui Provincial Cancer Hospital
• Principal Investigator: Zhongsheng Tong; Tianjin Cancer Hospital
• Principal Investigator: Jin Yang; The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
• Principal Investigator: Lihua Song; Shandong Cancer Hospital and Institute
• Principal Investigator: Xiuwen Wang; Qilu Hospital of Shandong University
• Principal Investigator: Yu Jiang; West China Hospital
• Principal Investigator: Yunjiang Liu; The Fourth Hospital of Hebei Medical University
• Principal Investigator: Jing Cheng; Wuhan Union Hospital, China
• Principal Investigator: Huihua Xiong; Tongji Hospital
• Principal Investigator: Xinhong Wu; Hubei Cancer Hospital
• Principal Investigator: Peng Shen; Zhejiang University
• Principal Investigator: Weimin Xie; Cancer Hospital Affiliated to Guangxi Medical University
• Principal Investigator: Xin Zhou; Chongqing University Cancer Hospital
• Principal Investigator: Li Ran; Cancer Hospital of Guizhou Province
• Principal Investigator: Yu Wang; Shanxi Province Cancer Hospital
• Principal Investigator: Jinnan Gao; Bethune Hospital of Shanxi Province
• Principal Investigator: Jingfen Wang; Linyi Cancer Hospital
• Principal Investigator: Liangming Zhang; Yantai Yuhuangding Hospital
• Principal Investigator: Xianhe Xie; First Affiliated Hospital of Fujian Medical University
• Principal Investigator: Ru Zeng; The First Affiliated Hospital of Xiamen University
• Principal Investigator: Airong Wang; Weihai Municipal Hospital
• Principal Investigator: Zhengqiu Zhu; The Affiliated Hospital of Xuzhou Medical University
• Principal Investigator: Sanyuan Sun; Xuzhou Central Hospital
• Principal Investigator: Qingshan Li; Affiliated Hospital of Chengde Medical College
• Principal Investigator: Aimin Zang; Affiliated Hospital of Hebei University
• Principal Investigator: Liuzhong Yang; The First Affiliated Hospital of Xinxiang Medical College
• Principal Investigator: Meili Sun; Jinan Central Hospital
• Principal Investigator: Liang Li; Zibo Central Hospital
• Principal Investigator: Guohua Yu; Weifang People's Hospital
• Principal Investigator: Xujuan Wang; Neijiang Second People's Hospital

More Information

• Responsible Party: RemeGen Co., Ltd.
• ClinicalTrials.gov Identifier: NCT04400695
• Other Study ID Numbers: RC48-C012
• First Posted: May 22, 2020
• Last Update Posted: November 26, 2021
• Last Verified: November 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Paclitaxel; Vinorelbine; Docetaxel; Capecitabine; Antineoplastic Agents, Phytogenic; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites